Bosh sahifaARCT • NASDAQ
add
Arcturus Therapeutics Holdings Inc
6,68 $
Seans yopilganidan keyin:(0,15%)+0,010
6,69 $
Yopilgan:13-mar, 19:01:11 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
7,00 $
Kunlik diapazon
6,64 $ - 7,25 $
Yillik diapazon
5,86 $ - 24,14 $
Bozor kapitalizatsiyasi
189,87 mln USD
Oʻrtacha hajm
468,98 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 7,20 mln | -68,39% |
Joriy xarajat | 14,03 mln | 13,30% |
Sof foyda | -29,08 mln | 3,09% |
Sof foyda marjasi | -404,10 | -206,60% |
Har bir ulushga tushum | -1,03 | 7,21% |
EBITDA | -30,62 mln | 5,99% |
Amaldagi soliq stavkasi | 0,01% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 230,91 mln | -2,58% |
Jami aktivlari | 271,15 mln | -21,19% |
Jami passivlari | 57,16 mln | -44,55% |
Umumiy kapital | 213,98 mln | — |
Tarqatilgan aksiyalar | 28,42 mln | — |
Narxi/balansdagi bahosi | 0,93 | — |
Aktivlardan daromad | -28,28% | — |
Kapitaldan daromad | -31,98% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -29,08 mln | 3,09% |
Operatsiyalardan naqd pul | -16,23 mln | -5 613,73% |
Sarmoyadan naqd pul | 88,00 ming | — |
Moliyadan naqd pul | 11,69 mln | 8 622,39% |
Naqd pulning sof oʻzgarishi | -4,45 mln | -2 867,33% |
Boʻsh pul | 50,91 mln | 434,06% |
Haqida
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
Tashkil etilgan
2013
Sayt
Xodimlar soni
109
